Pentosan Polysulfate

A Polysaccharide That Inhibits Angiogenesis by Binding Growth Factors
  • William D. Figg
  • James M. Pluda
  • Oliver Sartor
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Sodium pentosan polysulfate (PPS; xylanopolyhydrogensulfate, Fig. 1) is a semisynthetic sulfated heparinoid polysaccharide that has been used in Europe as an anticoagulant for nearly 30 yr (1–3) It is obtained from extract of beechwood shavings, and consists of a mixture of polymers with mol wt ranging from 1.8 to 9 kDa (mean 4.7 kDa) (3). This glycosaminoglycan is a highly negatively charged compound that contains 1.9 sulfate groups per monosaccharide unit.


Interstitial Cystitis Anticoagulant Activity Pentosan Polysulfate Euglobulin Clot Lysis Time Hepatic Triglyceride Lipase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bergqvist, D., Efsing, H. O., Hallbook, T., and Lindblad, B. (1980) Prevention of post-operative thromboembolic complications: a prospective comparison between dextran 70, dihydroergotamine heparin and sulfated polysaccharide. Acta Chir. Scand. 146, 559–568.PubMedGoogle Scholar
  2. 2.
    Bergqvist, D. and Ljungner, H. (1981) A comparative study of dextran 70 and a sulfated polysaccharide in the prevention of post-operative thromboembolic complications. Br. J. Surg. 68, 449–451.PubMedCrossRefGoogle Scholar
  3. 3.
    Joffe, S. (1976) Drug prevention of postoperative deep vein thrombosis: a comparative study of calcium heparinate and sodium pentosan polysulfate. Arch. Surg.111, 37–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Scully, M. and Kakker, V. (1984) Identification of heparin cofactor II as the principal plasma co-factor for the antithrombin activity of pentosan polysulfate (SP54). Thromb. Res. 36, 187–194.PubMedCrossRefGoogle Scholar
  5. 5.
    Klein-Soyer, C., Beretz, A., Cazenave, J. P., Wittendorp-Rechenmann, E., Vonesch, J. L., Rechenmann, R. V., Driot, F., and Maffrand, J. P. (1989) Sulfated polysaccharides modulate effects of acidic and basic fibroblast growth factors on repair of injured confluent human vascular endothelium. Arteriosclerosis 9, 147–153.PubMedCrossRefGoogle Scholar
  6. 6.
    Pienta, J. K., Murphy, B. C., Isaacs, W. B., Isaacs, J. T., and Coffey, D. S. (1992) Effect of pentosan, a novel cancer chemotherapeutic ageant, on prostate cancer cell growth and motility. Prostate 20, 233–241.PubMedCrossRefGoogle Scholar
  7. 7.
    Nguyen, N., Lehr, J. E., and Pienta, K. J. (1993) Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res. 13, 2143–2148.PubMedGoogle Scholar
  8. 8.
    Wellstein, A., Zugmaier, G., Califano, J. A., Kern, F., Paik, S., and Lippman, M. E. (1991) Tumor growth dependent on Kaposi’s sarcoma-derived fiibroblast growth factor inhibited by pentosan polysulfate. J. Natl. Cancer Inst. 83, 716–720.PubMedCrossRefGoogle Scholar
  9. 9.
    Herbert, J. M., Cottineau, M., Driot, F., Pereillo, J. M., and Maffrand, J. P. (1988) Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro. Biochem. Pharmacol. 37, 4281–4288.PubMedCrossRefGoogle Scholar
  10. 10.
    Zugmaier, G., Lippman, M. E., and Wellstein, A. (1992) Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J. Natl. Cancer Inst. 84, 1716–1724.PubMedCrossRefGoogle Scholar
  11. 11.
    Pluda, J. M., Shay, L. E., Foli, A., Tannenbaum, S., Cohen, P. J., Goldspiel, B. R., et al. (1993) Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi’s sarcoma. J. Natl. Cancer Inst. 85, 1585–1592.PubMedCrossRefGoogle Scholar
  12. 12.
    Gaffney, P. J. and Marsh, N. A. (1986) Effect ofpentosan polysulphate (SP54) on the human fibrinolytic system. Folia Haematol. 113, 262–271.Google Scholar
  13. 13.
    Barrowcliffe, T. W., Gray, E., Merton, R. E., Dawes, J., Jennings, C. A., Hubbard, A. R., and Thomas, D. P. (1986) Anticoagulant activities of pentosan polysulphate (hemoclar) due to release of hepatic triglyceride lipase (HTGL). Thromb. Haemost. 56, 202–206.PubMedGoogle Scholar
  14. 14.
    Soria, C., Soria, J., Ryckeweart, J. J., Holmer, E., and Caen, J. P. (1980) Anticoagulant activities of a pentosane polysulfate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb. Res. 19, 455–463.PubMedCrossRefGoogle Scholar
  15. 15.
    MacGregor, I., Dawes, J., Pepper, D. S., Prowse, C. V., and Stocks, J. (1985) Metabolism of sodium pentosan polysulfate as measured by a new competitive binding assay for sulfated polysaccharides:Google Scholar
  16. comparison with effects upon anticoagulant activity, lipolysis, and platelet a-granule protein. Thromb. Haemost. 53 411–414.Google Scholar
  17. 16.
    Ofosu, F. A., Blajchnan, M. A., Modi, G. J., and Smith, L. M. (1985) Importance of thrombin inhibition for the expression of the anticoagulant activity of heparin, dermatan sulfate, low molecular weight heparin, and pentosan polysulfate. Br. J. Haematol. 60, 695–704.PubMedCrossRefGoogle Scholar
  18. 17.
    Ofosu, F., Fernandez, F., Anvari, N, Caranobe, C., Dol, F., Cadroy, Y., et al. (1988) Further studies on the mechanisms for the anti-thrombotic effects of sulfated polysaccharides in rabbits. Thromb. Haemost. 60, 188–192.PubMedGoogle Scholar
  19. 18.
    Bergqvist, D., Falke, P., Jaroszewski, H., and Lamme, S. (1986) Comparison between heparin and a heparin analogue (sodium pentosan polysulphate) in the initial treatment of deep vein thrombosis. VASA 15, 77–80.PubMedGoogle Scholar
  20. 19.
    DeProst, D., Guerot, C., and Karsenty, F. (1985) Pentosan polysulfate: the effect on hemostasis of a continuous 3-day infusion. Clin. Pharmacol. Ther. 38, 171–182.CrossRefGoogle Scholar
  21. 20.
    Sie, P., Albarede, J., Robert, M., Bouloux, C., Lansen, J., Chigot, C., et al. (1986) Tolerance and biologic activity ofpentosan polysulfate after intramuscular or subcutaneous administration for 10 days in human volunteers. Thromb. Haemost. 55, 86–89.PubMedGoogle Scholar
  22. 21.
    Fischer, A. M., Merton, R. E., Marsh, N. A., Williams, S., Gaffney, P. J., Barrowcliffe, T. W., and Thomas, D. P. (1982) A comparison of pentosan polysulphate and heparin II: effects of subcutaneous injection. Thromb. Haemost. 47, 109–113.PubMedGoogle Scholar
  23. 22.
    Wagenvoord, R., Hendrix, H., Soria, C., and Hemker, H. C. (1988) Localization of the inhibitory site(s) of pentosan polysulfate in blood coagulation. Thrombo. Haemost. 60, 220–225.Google Scholar
  24. 23.
    Wagenvoord, R., Hendrix, H., Soria, C., and Hemker, H. C. (1985) Determination of the non-antithrombin III dependent inhibitor sites pentosan polysulfate in the blood coagulation. First International Symposium on Pentosan Polysulfate (abstract).Google Scholar
  25. 24.
    Paul, R., Herbert, J. M., Maffrand, J. P., Lansen, J., Modat, G., Pereillo, J. M., and Gordon, J. L. (1987) Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds. Thromb. Res. 24, 793–801.CrossRefGoogle Scholar
  26. 25.
    Nicosia, R. F. and Ottinetti, O. (1990) Growth of microvessels in serum-free matrix culture of rat aorta: a quantitative assay of angiogenesis in vitro. Lab. Invest. 63, 115–122.PubMedGoogle Scholar
  27. 26.
    Nicosia, R. F. and Ottinetti, A. (1990) Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell. Dev. Biol. 26, 119–128.PubMedCrossRefGoogle Scholar
  28. 27.
    McLeskey, S. W., Zhang, L., Trock, B. J., Kharbanda, S., Liu, Y., Gottardis, M. M., Lippman, M. E., and Kern, F. G. (1996) Effects of AGM-1470 and pentosan polysulphate on tumorigenicity. Br. J. Cancer 73, 1053–1062.PubMedCrossRefGoogle Scholar
  29. 28.
    Herbert, J. M. and Maffrand, J. P. (1991) Effect of pentosan polysulphate, standard heparin and related compounds on protein kinase C activity. Biochim. Biophys. Acta 1091, 432–441.PubMedCrossRefGoogle Scholar
  30. 29.
    Peters, M., Witvrouw, M., De Clercq, E., and Ruf, B. (1991) Pharmocokinetics of intravenous pentosan polysulphate in HIV-positive patients. AIDS 5, 1534, 1535 (letter).Google Scholar
  31. 30.
    Cadroy, Y., Dol, F., Caranobe, C., Sie, P., Houin, G., Picard, C., et al. (1987) Pharmcokinetics of 125Ipentosan polysulfate in the rabbit. Thromb. Res. 48, 373–378.PubMedCrossRefGoogle Scholar
  32. 31.
    MacGregor, I. R., Dawes, J., Pepper, D. S., Prowse, C. V., and Stocks, J. (1985) Metabolism of sodium pentosan polysulfate in man measured by a new competitve binding assay for sulphated polysaccharides: comparison with effects upon anticoagulant activity, lipolysis and platelet a-granule proteins. Thromb. Haemost. 53, 411–414.PubMedGoogle Scholar
  33. 32.
    Lush, R. M., Figg, W. D., Pluda, J. M., Bitton, R., Headlee, D., Kohler, D., et al. (1996) A Phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Ann. Oncol. 7, 939–944.PubMedCrossRefGoogle Scholar
  34. 33.
    Parker, B. W., Swain, S. M., Zugmaier, G., DeLap, R. L., Lippman, M. E., and Wellstein, A. (1993) Detectable inhibition of heparin binding growth factor activity in sera from patients treated with pentosan polysulfate. J. Natl. Cancer Inst. 85, 1068–1073.PubMedCrossRefGoogle Scholar
  35. 34.
    Swain, S. M., Parker, B., Wellstein, A., Lipppman, M. E., Steakley, C., and DeLap, R. (1995) Phase I trial of pentosan polysulfate. Invest. New Drugs. 13, 55–62.PubMedCrossRefGoogle Scholar
  36. 35.
    Marshall, J. L., Wellstein, A., Al-Kawas, F., Andris, R., and Hawkins, M. J. (1995) Phase I trial of orally administered pentosan polysulfate (PPS) in patients with advanced malignancies. 9th Annual Scientifiic Meeting of the Society for Biological Therapy: Biological Therapy of Cancer IX, Napa, CA, October 26–30, 1994, p. 29 (abstract).Google Scholar
  37. 36.
    Schwartsmann, G., Mans, D. R., Machado, V. L., Sander, E., Sprinz, E. and Kalakun, L. (1995) Phase II study of the basic fibroblast growth factor (b-FGF) inhibiting agent pentosan polysulfate (PPS) in patients with AIDS-related Kaposi’s sarcoma (AIDS-KS). Proceedings of the Annual Meeting of the American Association of Cancer Research (abstract) Tumori 82(4), 360–363.Google Scholar
  38. 37.
    Schwartsmann, G., Sprinz, E., Kalakun, L., Yamagushi, N., Sander, E., Grivicich, I., Koya, R., and Mans, D. R. (1996) Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi’s sarcoma. Tumori 82, 360–363.PubMedGoogle Scholar
  39. 38.
    Abramowicz, M., ed. (1997) Pentosan for interstitial cystitis. Med. Lett. Drugs Therap. 39, 53–56.Google Scholar
  40. 39.
    Moskowitz, M. O., Byrne, D. S., Callahan, H. J., Parson, C. L., Valderrama, E., and Moldwin R. M. (1994) Decreased expression of a glycoprotein component of bladder surface mucin (GP I) in interstitial cystitis. J. Urol. 151, 343–345.PubMedGoogle Scholar
  41. 40.
    Parsons, C. L., Lilly, J. D., and Stein, P. (1991) Epithelial dysfunction in nonbacterial cystitis (interstital cystitis). J. Urol. 145, 732–735.PubMedGoogle Scholar
  42. 41.
    Hwang,P.Auclair, B., Beechinor,D.Diment, M., and Einarson, T. R. (1997) Effiicacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. Urology 50 39–43.Google Scholar
  43. 42.
    Mulholland, S. G., Hanno, P., Parsons, C. L., Sant, G. R., and Staskin, D. R. (1990) Pentosan polysulfate sodium for therapy for interstitial cystitis: a double-blind placebo-controlled clinical study. Urology 35, 552–558.PubMedCrossRefGoogle Scholar
  44. 43.
    Fellstrom, B., Backman, U., Danielson, B., and Wikstrom, B. (1994) Treatment of renal calcium stone disease with the synthetic glycosaminoglycan pentosan polysulphate. World J. Urol. 12, 52–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • William D. Figg
  • James M. Pluda
  • Oliver Sartor

There are no affiliations available

Personalised recommendations